Cost ‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea

ConclusionsThe SOF+RBV is a cost ‐effective option for genotype 2 treatment‐naïve CHC patients, especially for the patients with liver cirrhosis in Korea.

Source: Journal of Gastroenterology and Hepatology - November 21, 2018 Category: Gastroenterology Authors: Wankyo Chung, Kyung ‐Ah Kim, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook‐Hyang Jeong Tags: Hepatology Source Type: research